Solid Biosciences
SLDB
127 hedge funds and large institutions have $502M invested in Solid Biosciences in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 38 increasing their positions, 36 reducing their positions, and 12 closing their positions.
1,465% more call options, than puts
Call options by funds: $4.33M | Put options by funds: $277K
108% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 12
25% more capital invested
Capital invested by funds: $400M → $502M (+$102M)
11% more funds holding
Funds holding: 114 → 127 (+13)
6% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 36
1.56% less ownership
Funds ownership: 106.06% → 104.5% (-1.6%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VPC
Vestal Point Capital
New York
|
+$8.6M |
| 2 |
BCM
Boxer Capital Management
San Diego,
California
|
+$3.51M |
| 3 |
AC
Armistice Capital
New York
|
+$3.13M |
| 4 |
Renaissance Technologies
New York
|
+$2.71M |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$2.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$16M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$10.5M |
| 3 |
BG
Bollard Group
Boston,
Massachusetts
|
-$1.76M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.65M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.55M |
SLDB Hedge Fund Activity: Q3 2025 in Review
127 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q3 2025, worth a combined $502M — up 25% from $400M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SLDB positions and 12 closed out — a net gain of 13 holders — while 38 added to existing stakes and 36 trimmed.
The largest buyer was Vestal Point Capital, adding an estimated $8.6M. The largest seller was Adage Capital Partners, cutting an estimated $16M.
- 127 institutional investors held Solid Biosciences (SLDB) as of Q3 2025, up from 114 in Q2 2025.
- Funds reported $502M of Solid Biosciences stock for Q3 2025, up 25% quarter-over-quarter.
- 25 funds opened new Solid Biosciences positions in Q3 2025 and 12 closed out, a net change of +13 holders.
- The largest Solid Biosciences buyer in Q3 2025 was Vestal Point Capital, an estimated $8.6M added.
- The largest Solid Biosciences seller in Q3 2025 was Adage Capital Partners, an estimated $16M sold.
Based on aggregated 13F filings for Q3 2025.